Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: anti-HPV-16 E6 TCR; HPV-16 E6 TCR gene therapy

Latest Information Update: 04 Oct 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kite Pharma; National Cancer Institute (USA)
  • Class Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Anal cancer; Cervical cancer; Oropharyngeal cancer; Penile cancer; Vulvovaginal cancer

Most Recent Events

  • 03 Oct 2017 Gilead Sciences acquired Kite Pharma
  • 29 Jun 2017 National Cancer Institute plans a phase I trial for Cervical intraepithelial neoplasia in USA (NCT03197025)
  • 02 Jun 2017 Adverse events and efficacy data from a phase II trial in HPV-associated Anal cancer, Cervical cancer, Oropharyngeal cancer, Penile cancer, Vulvovaginal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top